Search results for "GLUCOCORTICOIDS"

showing 10 items of 162 documents

Glucocorticoid excess and COVID-19 disease

2020

AbstractThe pandemic of coronavirus disease (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is causing high and rapid morbidity and mortality. Immune system response plays a crucial role in controlling and resolving the viral infection. Exogenous or endogenous glucocorticoid excess is characterized by increased susceptibility to infections, due to impairment of the innate and adaptive immune system. In addition, diabetes, hypertension, obesity and thromboembolism are conditions overrepresented in patients with hypercortisolism. Thus patients with chronic glucocorticoid (GC) excess may be at high risk of developing COVID-19 infection with a sever…

cortisol; cushing’s syndrome; glucocorticoid; immune system; infections; SarsCoV2Endocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseasemedicine.disease_causeBioinformaticsSarsCoV2InfectionsArticleCortisolSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineImmune systemEndocrinologyGlucocorticoidSarsCoV2.Diabetes mellitusPandemicMedicineHumans030212 general & internal medicineCushing SyndromeGlucocorticoidsPandemicsCoronavirusbusiness.industrySARS-CoV-2COVID-19medicine.diseaseAcquired immune systemObesityImmune systemCushing’s syndromebusinessInfectionGlucocorticoidmedicine.drugReviews in Endocrine & Metabolic Disorders
researchProduct

Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis

2020

Although most patients with ulcerative colitis should be given topical treatment, different studies have shown that they are underused in clinical practice. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission are evaluated. Finally, a series of recommendations addressed to patients are giv…

glucocorticoidesmedicine.medical_specialtycolitisAdministration TopicalhumanosAnti-Inflammatory AgentsTopical treatmentmesalamina03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMesalazineTopical treatmentmedicineMesalazinaHumansCorticosteroidsMesalamineGlucocorticoidsCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseantiinflamatoriosUlcerative colitisDermatologyClinical PracticechemistryUlcerative colitis030220 oncology & carcinogenesisDisease remission030211 gastroenterology & hepatologyColitis UlcerativeMesalazinebusiness
researchProduct

Are zinc-bound metallothionein isoforms (I+II and III) involved in impaired thymulin production and thymic involution during ageing?

2004

Abstract Background With advancing age, thymic efficiency shows progressive decline due to thymic involution allowing impaired cell-mediated immunity and the appearance of age-related diseases. The intrinsic cause of thymic involution is still undefined. Chronic inflammation and high glucocorticoids (GCs) may be involved. However, transgenic mice, with increased GC sensitivity and over expression of GC receptors, display delayed age-associated thymic involution. This fact suggests that other substances may affect thymic involution. Among them, both isoforms of metallothioneins (MTs) I+II and III are the major candidates because their increments leads to organ atrophy in constant stress and …

lcsh:Immunologic diseases. AllergyThymic involutionIL-6glucocorticoidsResearchzinclcsh:Geriatricslcsh:RC952-954.6TECslongevityinflammationageinglcsh:RC581-607MetallothioneinsImmunityageing : IA
researchProduct

 A Mechanistic Approach to theIn VivoAnti-Inflammatory Activity of Sesquiterpenoid Compounds Isolated fromInula viscosa

2001

The present study was designed to examine the anti-inflammatory activity of the sesquiterpenoids ilicic acid and inuviscolide, isolated from Inula viscosa, on cell degranulation, leukotriene biosynthesis, neurogenic drive and glucocorticoid-like interactions. Swiss female mice were used to measure the ear oedema induced by phorbol esters or ethyl phenylpropiolate (EPP), and the paw oedema induced by phospholipase A(2) (PLA(2)) or serotonin. Drug treatment consisted of one topically-applied dose in the ear models and a subcutaneous or intraperitoneal injection in the paw models. Quantitative analysis of leukotriene B(4) (LTB(4)) formation was performed on rat peritoneal neutrophils by high p…

medicine.drug_classLeukotriene B4medicine.medical_treatmentIntraperitoneal injectionPharmaceutical SciencePharmacologyBiologyPharmacognosyLeukotriene B4Cell DegranulationAnti-inflammatoryAnalytical ChemistryInhibitory Concentration 50MiceStructure-Activity Relationshipchemistry.chemical_compoundPhospholipase A2In vivoDrug DiscoverymedicineAnimalsDrug InteractionsGlucocorticoidsInflammationPharmacologyPhospholipase ADose-Response Relationship DrugMolecular StructureAnti-Inflammatory Agents Non-SteroidalOrganic ChemistryComplementary and alternative medicineBiochemistryMechanism of actionchemistrybiology.proteinMolecular MedicineFemaleInulaPlant Preparationsmedicine.symptomSesquiterpenesPhytotherapyPlanta Medica
researchProduct

COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficien…

2020

In November 2019, the Italian Society of Endocrinology (SIE) has published a consensus statement on the tailoring of glucocorticoid replacement in adrenal insufciency [1]. A few months later, a novel severe acute respiratory syndrome coronavirus (SARS-CoV2) has been recognized as responsible for COVID-19. The outbreak has now reached pandemic level, with a high global mortality rate [2]. From February on, Italy has experienced an exponential rise in the infected which is estimated to reach 200,000 people, with an overall lethality of approximately 10% [3]. A recent Chinese series of nearly 50,000 patients with confrmed COVID-19 infection found that approximately one-out-of-fve (19%) evolve …

medicine.medical_specialty2019-20 coronavirus outbreakConsensusCoronavirus disease 2019 (COVID-19)Hormone Replacement TherapyEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralConsensuEndocrinologyGlucocorticoidmedicineAdrenal insufficiencyHumansSteroids.Hormone replacement therapyViralIntensive care medicinePandemicsAdrenal insufficiency; COVID-19; Glucocorticoids; SARS-CoV2GlucocorticoidsPandemicbusiness.industryCoronavirus InfectionCOVID-19Pneumoniamedicine.diseaseCOVID-19 Drug TreatmentItalyExpert opinionSARS-CoV2SteroidsbusinessCoronavirus InfectionsCoronavirus InfectionsAdrenal insufficiencyHuman
researchProduct

Management of oral Graft versus Host Disease with topical agents: a systematic review

2015

Background: Oral Graft-versus-Host Disease (oGvHD) is a common complication of haematopoietic stem cell transplantation. Choosing the right topical application to be used intra orally can be a challenge. Consequently, the aim of this work is to review the effectiveness and safety of topical agents currently used in the management of the inflammatory mucosal lesions encountered in oGVHD. Material and Methods: We carried out electronic searches of publications up to May 2015 of the databases Pubmed, National Library of Medicine’s Medline, Embase and the Cochrane Central Register of Controlled Clinical trials to identify potentially relevant studies (keywords: “oral”, “graft”, “versus”, “host”…

medicine.medical_specialtyAdministration TopicalGraft vs Host DiseaseOdontologíaReviewDisease03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineGlucocorticoidsGeneral Dentistrybusiness.industryMucosal lesions030206 dentistryMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgeryTransplantationGraft-versus-host diseaseOtorhinolaryngologyTopical agents030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryStem cellMouth DiseasesbusinessComplicationImmunosuppressive Agents
researchProduct

Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids.

2007

Dual specificity phosphatase DUSP1 (otherwise known as mitogen-activated phosphatase 1 or MKP-1) dephosphorylates MAPKs, particularly p38, and negatively regulates innate immunity. Recent studies have shown that the DUSP1 gene is transcriptionally up-regulated by glucocorticoids (GCs) and that the antiinflammatory action of GCs is impaired in DUSP1-/- mice. Here we show that GC-mediated dephosphorylation of ERK-1 and ERK-2 activated by IgE receptor cross-linking is unimpaired in bone marrow-derived mast cells (BMMCs) of DUSP1-/- mice. Dephosphorylation of phospho-p38 MAPK is impaired but only at early times of GC treatment. Proinflammatory cytokine and chemokine gene expression (CCL2, IL-6,…

medicine.medical_specialtyChemokinePhosphataseImmunoglobulin Ep38 Mitogen-Activated Protein KinasesProinflammatory cytokineDephosphorylationMiceEndocrinologyInternal medicineSepsisDual-specificity phosphatasemedicineAnimalsGenetic Predisposition to DiseaseMolecular BiologyAnaphylaxisGlucocorticoidsMice KnockoutMitogen-Activated Protein Kinase 1Mice Inbred C3HMitogen-Activated Protein Kinase 3biologyInterleukin-6Tumor Necrosis Factor-alphaDegranulationDual Specificity Phosphatase 1General MedicineMice Inbred C57BLEndocrinologyGene Expression RegulationMice Inbred DBAbiology.proteinCytokinesTumor necrosis factor alphaMolecular endocrinology (Baltimore, Md.)
researchProduct

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency

2019

Background Dual-release hydrocortisone (DR-HC) improves metabolism in patients with adrenal insufficiency. The aims of this study were to compare the cardiovascular and metabolic effects of conventional glucocorticoids (GCs) vs. DR-HC and of high vs. low doses of GCs, after 48 months of observation. Methods We selected 27 patients on hydrocortisone (mean dose 17.5 ± 4.2 mg/day) and 20 patients on cortisone acetate (mean dose 37.5 ± 12.1 mg/day) who maintained this treatment (group A) and 53 patients switched to DR-HC (mean dose 22 ± 4.8 mg/day) (group B). At baseline and after 48 months, clinical and metabolic parameters and Framingham Risk Score (FRS) were obtained. Results After 48 month…

medicine.medical_specialtyDiabetes mellituWaistDual releaseEndocrinology Diabetes and MetabolismUrology030209 endocrinology & metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyConventional glucocorticoidGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal MedicineAdrenal insufficiencymedicineHydrocortisonelcsh:RC648-665Framingham Risk Scorebusiness.industryResearchconventional glucocorticoidsmedicine.diseaseCardiovascular riskBlood pressure030220 oncology & carcinogenesisdiabetes mellitusDual-release hydrocortisonebusinessAdrenal insufficiencymedicine.drug
researchProduct

Expressional down-regulation of neuronal-type nitric oxide synthase I by glucocorticoids in N1E-115 neuroblastoma cells.

1998

Neuronal-type nitric oxide synthase (NOS I) is involved in ischemia-induced brain damage, and glucocorticoids have been reported to protect from brain damage. This prompted us to investigate if the activity or expression of NOS I was influenced by glucocorticoids. We used the murine neuroblastoma cell line N1E-115 as our experimental model. Short-term incubation (30 min) of the N1E-115 cells with dexamethasone (10 nM to 1 microM) or hydrocortisone (100 nM to 10 microM) did not change the enzymatic activity of NOS I. However, the glucocorticoids inhibited NOS I mRNA expression in a concentration-dependent fashion (down to 53.3 +/- 2. 5% of control). In time-course experiments with 100 nM dex…

medicine.medical_specialtyDown-RegulationNitric Oxide Synthase Type IBiologyNitric OxideDexamethasonechemistry.chemical_compoundMiceNeuroblastomaInternal medicinemedicineTumor Cells CulturedAnimalsRNA MessengerGlucocorticoidsDexamethasonePharmacologyNeuronsMessenger RNAAntiglucocorticoidMifepristoneNitric oxide synthaseBlotEndocrinologychemistryCell culturebiology.proteinMolecular MedicineNitric Oxide SynthaseGlucocorticoidmedicine.drugMolecular pharmacology
researchProduct

Diabetes mellitus secondary to Cushing's disease

2018

Associated with important comorbidities that significantly reduce patients’ overall wellbeing and life expectancy, Cushing’s disease (CD) is the most common cause of endogenous hypercortisolism. Glucocorticoid excess can lead to diabetes, and although its prevalence is probably underestimated, up to 50% of patients with CD have varying degrees of altered glucose metabolism. Fasting glycemia may nevertheless be normal in some patients in whom glucocorticoid excess leads primarily to higher postprandial glucose levels. An oral glucose tolerance test should thus be performed in all CD patients to identify glucose metabolism abnormalities. Since diabetes mellitus (DM) is a consequence of cortis…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDisease030204 cardiovascular system & hematologyCarbohydrate metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineInsulin resistanceCortisol-lowering medication; Cushing's disease; Diabetes; Glucocorticoids; Insulin resistance; Endocrinology Diabetes and MetabolismEndocrinologyInternal medicineDiabetes mellitusmedicineGlucocorticoidslcsh:RC648-665business.industryDiabetesInsulin resistanceCushing's diseaseCushing’s diseasemedicine.diseaseDiabetes and MetabolismEndocrinologyPostprandialCortisol-lowering medicationCushing's diseasePituitary surgerybusinessGlucocorticoidmedicine.drug
researchProduct